SynCardia Wins Copper Cactus Award for Innovation
and Two Best in Biz Awards
Best in Biz Awards Include: Product of the Year – Gold Winner, Executive of the Year – Silver Winner
TUCSON, Ariz. – Nov. 29, 2012 – SynCardia Systems, Inc., manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total
Artificial Heart, announced today that it has been honored with three awards in
Best in Biz Awards, announced Nov. 12
- Best New Product of the Year
Gold Winner: Freedom® portable driver
The Freedom portable driver is the world’s first wearable power supply for the SynCardia temporary Total Artificial Heart. Weighing 13.5 pounds, the Freedom portable driver allows stable Total Artificial Heart patients who meet discharge criteria to wait for a matching donor heart at home and in their communities instead of in the hospital.
- Executive of the Year
Silver Winner: Michael Garippa, SynCardia Chairman/CEO/President
Although many companies in the mechanical circulatory support industry are struggling to be profitable, SynCardia’s implants, revenue and profit for the first 9 months of 2012 have exceeded the company's best 12-month totals to date. In 2012, SynCardia is on track to achieve nearly 500% growth over 2009 thanks to Mr. Garippa’s leadership.
Winners were selected from more than 400 entries by an independent panel of 32 judges from top-tier news, business and technology publications, broadcast outlets and analyst firms, including ABC, Businessweek, Entrepreneur, Forbes, FOX News and USA Today.
Copper Cactus Awards, announced Nov. 13
- Nextrio Innovation through Technology Winner
As part of the Copper Cactus Awards presented by the Tucson Chamber of Commerce, SynCardia was honored for exceptional innovation through technology for its Freedom portable driver.
Since 2011, SynCardia has been honored with more than a dozen prestigious awards for its accomplishments in the fields of business, medicine and technology, including being ranked #20 among the "World's 50 Most Innovative Companies" by Fast Company Magazine and among "America's Most Promising Companies" by Forbes Magazine.
The Freedom portable driver is CE approved for use in Europe and undergoing an FDA-approved Investigational Device Exemption (IDE) clinical study in the U.S.
CAUTION – The Freedom portable driver is an investigational device, limited by United States law to investigational use.
About the SynCardia temporary Total Artificial Heart
SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,250 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.
Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. It is the only device that eliminates the symptoms and source of end stage biventricular failure. Unlike a donor heart, the Total Artificial Heart is immediately available at 93 SynCardia Certified Centers worldwide with 35 others in the process of certification.
The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.
Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"
In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition.